Hadziyannis SJ - Search Results

1

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.

Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H Jr, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ. Reddy KR, et al. Among authors: hadziyannis sj. J Viral Hepat. 2008 Feb;15(2):129-36. doi: 10.1111/j.1365-2893.2007.00901.x. J Viral Hepat. 2008. PMID: 18184196

2

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.

Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, Wright TL, Fried M. Reddy KR, et al. Clin Gastroenterol Hepatol. 2007 Jan;5(1):124-9. doi: 10.1016/j.cgh.2006.10.008. Epub 2006 Dec 28. Clin Gastroenterol Hepatol. 2007. PMID: 17196435

3

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.

Zeuzem S, Rodríguez-Torres M, Rajender Reddy K, Marcellin P, Diago M, Craxi A, Pockros P, Rizzetto M, Bernstein D, Shiffman ML, Lin A, Tatsch F, Hadziyannis S. Zeuzem S, et al. J Viral Hepat. 2012 Nov;19(11):766-74. doi: 10.1111/j.1365-2893.2012.01624.x. Epub 2012 May 14. J Viral Hepat. 2012. PMID: 23043383

4

Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.

Reddy KR, Messinger D, Popescu M, Hadziyannis SJ. Reddy KR, et al. Among authors: hadziyannis sj. J Viral Hepat. 2009 Oct;16(10):724-31. doi: 10.1111/j.1365-2893.2009.01122.x. J Viral Hepat. 2009. PMID: 19486469 Clinical Trial.

5

Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.

Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. Marcellin P, et al. J Hepatol. 2012 Jun;56(6):1276-82. doi: 10.1016/j.jhep.2011.12.026. Epub 2012 Feb 4. J Hepatol. 2012. PMID: 22314423

6

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.

Marcellin P, Roberts SK, Reddy KR, Harrison SA, Jensen DM, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F, Rizzetto M. Marcellin P, et al. Expert Opin Drug Saf. 2012 Nov;11(6):901-9. doi: 10.1517/14740338.2012.721927. Epub 2012 Sep 4. Expert Opin Drug Saf. 2012. PMID: 22943161

7

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Hadziyannis SJ, et al. Ann Intern Med. 2004 Mar 2;140(5):346-55. doi: 10.7326/0003-4819-140-5-200403020-00010. Ann Intern Med. 2004. PMID: 14996676 Clinical Trial.

8

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.

Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Jensen DM, et al. Among authors: hadziyannis sj. Hepatology. 2006 May;43(5):954-60. doi: 10.1002/hep.21159. Hepatology. 2006. PMID: 16628671

9

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.

Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P. Bruno S, et al. Among authors: hadziyannis sj. Hepatology. 2010 Feb;51(2):388-97. doi: 10.1002/hep.23340. Hepatology. 2010. PMID: 19918980 Clinical Trial.

10

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, Shiffman ML, Hadziyannis SJ, Schmidt WN, Jacobson IM, Bárcena R, Schiff ER, Shaikh OS, Bacon B, Marcellin P, Deng W, Esteban-Mur R, Poynard T, Pedicone LD, Brass CA, Albrecht JK, Gordon SC. Manns MP, et al. Among authors: hadziyannis sj. J Viral Hepat. 2013 Aug;20(8):524-9. doi: 10.1111/jvh.12074. Epub 2013 Mar 3. J Viral Hepat. 2013. PMID: 23808990 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

245 results

Search Page

Filters